- Home
- NRGV vs IMA Comparison
NRGV vs IMA Comparison
Compare NRGV & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- IMA
- Stock Information
- Founded
- NRGV 2017
- IMA 2019
- Country
- NRGV United States
- IMA United States
- Employees
- NRGV N/A
- IMA N/A
- Industry
- NRGV Industrial Machinery/Components
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRGV Miscellaneous
- IMA Health Care
- Exchange
- NRGV Nasdaq
- IMA Nasdaq
- Market Cap
- NRGV 133.4M
- IMA 159.1M
- IPO Year
- NRGV N/A
- IMA N/A
- Fundamental
- Price
- NRGV $2.29
- IMA $9.14
- Analyst Decision
- NRGV Buy
- IMA
- Analyst Count
- NRGV 3
- IMA 0
- Target Price
- NRGV $1.58
- IMA N/A
- AVG Volume (30 Days)
- NRGV 2.0M
- IMA 41.0K
- Earning Date
- NRGV 11-11-2025
- IMA 01-01-0001
- Dividend Yield
- NRGV N/A
- IMA N/A
- EPS Growth
- NRGV N/A
- IMA N/A
- EPS
- NRGV N/A
- IMA N/A
- Revenue
- NRGV $51,716,000.00
- IMA $4,300,000.00
- Revenue This Year
- NRGV $314.58
- IMA N/A
- Revenue Next Year
- NRGV $39.00
- IMA N/A
- P/E Ratio
- NRGV N/A
- IMA N/A
- Revenue Growth
- NRGV N/A
- IMA N/A
- 52 Week Low
- NRGV $0.60
- IMA $7.95
- 52 Week High
- NRGV $2.70
- IMA $23.28
- Technical
- Relative Strength Index (RSI)
- NRGV 70.49
- IMA N/A
- Support Level
- NRGV $1.73
- IMA N/A
- Resistance Level
- NRGV $2.33
- IMA N/A
- Average True Range (ATR)
- NRGV 0.18
- IMA 0.00
- MACD
- NRGV 0.00
- IMA 0.00
- Stochastic Oscillator
- NRGV 94.12
- IMA 0.00
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.